The post As per the Nikkei Report appeared on BitcoinEthereumNews.com. Japan’s top financial regulators are seeking to approve the first spot crypto ETF in two The post As per the Nikkei Report appeared on BitcoinEthereumNews.com. Japan’s top financial regulators are seeking to approve the first spot crypto ETF in two

As per the Nikkei Report

  • Japan’s top financial regulators are seeking to approve the first spot crypto ETF in two years.
  • Nomura Holdings and SBI Holdings are among the firms in the country expected to launch crypto ETFs.
  • Japan ranked among the top 20 global nations in crypto adoption in 2025 according to Chainalysis.

Japan is poised to have its first spot crypto exchange-traded funds (ETFs) in 2028. According to a report from Nikkei, Japan is seeking to follow the United States in regulating the crypto market to catalyze mainstream adoption and increase its tax collection.

Japan Regulators Eyes Spot Crypto 

According to the report, the Financial Services Agency (FSA) plans to add cryptocurrencies to its list of assets eligible for ETFs as early as 2028. The report noted that the FSA is seeking to strengthen the cryptocurrency rules in the country in order to protect investors.

The approval of the spot crypto ETFs will start with the top digital assets led by Bitcoin (BTC), Ethereum (ETH), XRP, Cardano (ADA), and Dogecoin (DOGE). Several financial groups in the country, led by SBI Holdings, have been engaged with the cryptocurrency industry in the past.

The rising demand for digital assets in Japan has pushed the FSA to signal its willingness to add crypto to ETF lists. As such, several spot crypto ETFs will be listed on the Tokyo Stock Exchange (TSE) in the subsequent years.

Related: Bank of Japan Holds Rates at 30-Year High as Debt and Yen Risks Loom for Crypto

Why Now?

Japan has closely followed the United States in the regulation of crypto assets. Furthermore, the United States has several crypto ETFs trading, with Bitcoin’s boasting more than $113 billion in total assets.

Under President Donald Trump, the United States has expedited the legalization of crypto assets. For instance, the U.S. Securities and Exchange Commission (SEC) removed barriers for approving spot crypto ETFS through adopting the generic listing standards in September 2025.

The Japanese and U.S. authorities have collaborated in boosting their economies. For instance, Japan’s Finance Minister Satsuki Katayama welcomed the decision by the U.S. to buy the Yen through the Federal Reserve Bank of New York.

Bigger Picture

Japan has grown into a crypto hub in Asia through clear regulatory frameworks. According to Chainalysis’ global crypto adoption index for 2025, Japan ranked 19, which is higher than China at 35 but lower than Russia at 10 and South Korea at 15.

The FSA has defined Bitcoin and Ethereum as digital assets, thus regulated under the Payment Services Act (PSA). As such, crypto businesses seeking to operate in Japan must be regulated under the strict rules of the FSA.

Meanwhile, the FSA is planning to review and submit a bill to the parliament in 2026 to introduce changes to crypto regulations. Earlier, the FSA planned to amend the current progressive tax rate on individual crypto gains, which can reach 55%, to be replaced by a flat tax rate of about 20%.

As such, the FSA will help attract more institutional investment in Japan, to boost economic growth.

Related: Arthur Hayes: Bitcoin “Very Bullish” If Fed Expands Balance Sheet via Yen Support

Disclaimer: The information presented in this article is for informational and educational purposes only. The article does not constitute financial advice or advice of any kind. Coin Edition is not responsible for any losses incurred as a result of the utilization of content, products, or services mentioned. Readers are advised to exercise caution before taking any action related to the company.

Source: https://coinedition.com/japan-eyes-spot-crypto-etfs-by-2028-as-per-the-nikkei-report/

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26